Retatrutide: experiences

Two very different kinds of experience are reported under the name retatrutide. One is from clinical trials, where participants received Lilly's drug under supervision. The other is from people who used products sold online as retatrutide, whose contents are unknown. The two should not be mixed up: a side effect in the second group may come from the peptide, from a wrong amount, or from something else in the vial.

In the trials

In the phase 2 trial, “The most common adverse events in the retatrutide groups were gastrointestinal”.[1] The investigators also reported a change in pulse: “Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter”.[1]

Poison centre reports

US poison centres have seen a steep rise in calls about products identified as retatrutide. These figures come from CBS News reporting of America's Poison Centers data, relayed by secondary sources; we did not find them in a publication of the association itself. A summary of that reporting says the centres “logged 862 exposures involving products identified as retatrutide in July” to September, “up from 460 in April” to June “and 249 in January” to March.[2] Drug Topics, citing earlier CBS reporting, wrote that “human exposures to retatrutide reported to US poison centers surged by 265% in the first 4 months of 2026 compared with the end of 2025”.[3] The association's own caution applies: “exposures do not necessarily represent poisonings or overdoses”.[4]

Hospital cases

Victoria's health department reported that “there have been six cases of acute liver injury in Victoria in people who have used an unapproved peptide product, labelled as Retatrutide”, and said that “additional contaminants may be contributing to the observed liver toxicity”.[5] In the US, the advocacy group Public Citizen counted “14 reported hospitalizations connected to retatrutide” as of June 2026.[6]

A case report in Cureus describes a patient with type 1 diabetes and gastroenteritis who had used an online-sourced product sold as retatrutide; the patient's “recurrent hypoglycaemia required intravenous dextrose and insulin dose adjustment”.[7] The author notes that “While causation cannot be established”, the “exposure may have contributed to symptom severity”.[7]

Reported deaths

According to CBS News, as relayed by Gizmodo, the FDA has received reports of two deaths involving products sold as retatrutide, and “CBS News obtained the reports via a Freedom of Information Act request”.[8] One describes “a 49-year-old patient who died after experiencing severe dehydration, malnutrition, and a cardiac arrest”.[8] Newsweek reported that “The deaths were not connected to Eli Lilly” trials.[9] These are unverified reports, not findings: as Gizmodo put it, “these reports alone cannot prove whether a drug is responsible for a person” falling ill or dying, and none can say what was in the product used.[8]

For the full account of these reports, what tested vials held and the warning signs, see Retatrutide from a research vial.

References

1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (Jastreboff et al., N Engl J Med 2023;389:514-526) — PubMed (New England Journal of Medicine)
2. Retatrutide news today (last verified October 14, 2026) — The Rx Index
3. Some providers prescribe unapproved retatrutide for weight loss at alarming rate (June 10, 2026) — Drug Topics
4. GLP-1 (Track Emerging Hazards) — America's Poison Centers
5. Toxicity linked to unapproved peptide product labelled Retatrutide (health alert, 19 June 2026) — Department of Health, Victoria, Australia
6. Hospitalizations, Enforcement Gaps, Influencers Tied to Unapproved Retatrutide Products (June 16, 2026) — Public Citizen
7. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis (Branine, Cureus 2026;18(8):e115260) — PubMed (Cureus)
8. The most powerful weight loss drug yet isn't approved, but its black market may already be turning deadly (Ed Cara, October 14, 2026) — Gizmodo
9. What is retatrutide? (October 2026) — Newsweek